Peter A Forsyth

Nov 20, 2024 | onclive.com | Peter A Forsyth

"We are lucky that we have seen people quickly and early, so they're still in pretty good shape. Sometimes when people have this disease, it's too advanced by the time you see them or by the time they get the appropriate care, because it's hard to recognize this disease.

Oct 31, 2024 | tandfonline.com | Peter A Forsyth |Yuying Li

ABSTRACTWe discuss a neural network approach, which does not rely on dynamic programming techniques, to solve dynamic portfolio optimization problems subject to multiple investment constraints. The approach allows for objectives of a very general form encompassing both time-consistent and time-inconsistent objectives, as well as objectives requiring multi-level optimization. The number of parameters of the neural network remains independent of the number of portfolio rebalancing events.

Aug 27, 2024 | onclive.com | Peter A Forsyth

Peter Forsyth, MD, chairman, Neuro-Oncology Program, Moffitt Cancer Center; professor of oncology, the University of South Florida, discusses next steps for the investigation of dose-escalating intrathecal dendritic cells (cDC1s) targeting HER2/HER3 in patients with leptomeningeal disease.

Jun 18, 2024 | onclive.com | Peter A Forsyth

Peter Forsyth, MD, chairman, Neuro-Oncology Program, Moffitt Cancer Center; professor, oncology, the University of South Florida, discusses the importance of evaluating leptomeningeal disease in a first-in-human phase 1 trial (NCT05809752) of dose-escalating intrathecal dendritic cells (cDC1s) targeting HER2/HER3 in patients with triple-negative breast cancer (TNBC) or HER2-positive breast cancer.

Jun 11, 2024 | onclive.com | Peter A Forsyth

CommentaryVideoJune 11, 2024Author(s):Peter Forsyth, MD, discusses a study of intrathecal dendritic cells in patients with leptomeningeal disease from TNBC or HER2-positive breast cancer.